The life sciences industry is in the midst of a quiet revolution, one that is unfolding not in sprawling clinical trial sites or blockbuster FDA approvals, but inside compact laboratory incubators where miniature, self-organizing replicas of human organs are being grown, monitored, and analyzed at unprecedented scale. Automated organoid culturing sits at the heart of this revolution, merging the biological complexity of three-dimensional tissue models with the precision, throughput, and reproducibility that only robotic and intelligent systems can deliver.
Organoids, tiny, stem cell-derived structures that recapitulate the architecture and function of real human or...
